Literature DB >> 11992626

Dual coupling of MT(1) and MT(2) melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure.

Renee S MacKenzie1, Melissa A Melan, Deepshikha K Passey, Paula A Witt-Enderby.   

Abstract

In this investigation, we wanted to determine whether MT(1) or MT(2) melatonin receptors are capable of coupling to the phosphoinositide (PI) signal transduction cascade. In addition, we wanted to assess the effects of chronic melatonin exposure on MT(1) and MT(2) melatonin receptor-mediated stimulation of PI hydrolysis. We also assessed the effects of chronic melatonin exposure on other parameters of the MT(2) melatonin receptor function including total specific 2-[125I]-iodomelatonin binding, the affinity of melatonin for the receptor, and melatonin (1nM)-mediated inhibition of cyclic 3',5'-adenosine monophosphate (cAMP) accumulation. Investigation of the PI signal transduction cascade activated by either the MT(1) or MT(2) melatonin receptor expressed in Chinese hamster ovary (CHO) cells showed that melatonin (1pM to 1mM) was able to stimulate the formation of PIs to approximately 40-60% over basal [EC(50): MT(1)=29nM (2-300nM) and MT(2)=1.1nM (0.32-3.5nM), N=5]. This response was mediated via receptors based upon the findings that melatonin did not stimulate the formation of PIs in CHO cells devoid of receptor and that antagonism of MT(2) melatonin receptors by 4P-PDOT (AH 024; 4-phenyl-2-propionamidotetralin) attenuated melatonin-mediated stimulation of PI hydrolysis in CHO cells expressing the MT(2) melatonin receptor. The consequence of chronic melatonin exposure on MT(1) and MT(2) receptor function was also examined. Pretreatment of either MT(1)- or MT(2)-CHO cells with melatonin (1 microM for 5hr) resulted in: (a) a complete loss of melatonin-mediated stimulation of PI hydrolysis, and (b) an attenuation of melatonin (1nM)-mediated inhibition of forskolin-induced cAMP accumulation by approximately 20-40%. The desensitization of the PI hydrolysis signal transduction cascades coupled to either MT(1) or MT(2) melatonin receptors following chronic melatonin exposure was not due to depleted phospholipid pools, to elevated basal levels, or to decreases in receptor affinity and density. This dual coupling of melatonin receptors to different signal transduction cascades may contribute to the diversity of melatonin receptor function in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992626     DOI: 10.1016/s0006-2952(01)00881-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

2.  Role of melatonin on diabetes-related metabolic disorders.

Authors:  Javier Espino; José A Pariente; Ana B Rodríguez
Journal:  World J Diabetes       Date:  2011-06-15

3.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

4.  Melatonin potentiates glycine currents through a PLC/PKC signalling pathway in rat retinal ganglion cells.

Authors:  Wen-Jie Zhao; Min Zhang; Yanying Miao; Xiong-Li Yang; Zhongfeng Wang
Journal:  J Physiol       Date:  2010-06-02       Impact factor: 5.182

5.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

Review 6.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

8.  Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.

Authors:  Maud Kamal; Florence Gbahou; Jean-Luc Guillaume; Avais M Daulat; Abla Benleulmi-Chaachoua; Marine Luka; Patty Chen; Dina Kalbasi Anaraki; Marc Baroncini; Clotilde Mannoury la Cour; Mark J Millan; Vincent Prevot; Philippe Delagrange; Ralf Jockers
Journal:  J Biol Chem       Date:  2015-03-13       Impact factor: 5.157

9.  Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice.

Authors:  Hang Sun; Xingchun Wang; Jiaqi Chen; Kexiu Song; Aaron M Gusdon; Liang Li; Le Bu; Shen Qu
Journal:  Lipids Health Dis       Date:  2016-11-23       Impact factor: 3.876

Review 10.  Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon.

Authors:  Elmar Peschke; Ina Bähr; Eckhard Mühlbauer
Journal:  Int J Mol Sci       Date:  2013-03-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.